Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients

Launched by INSTITUT BERGONIÉ · May 28, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how well a new test called liquid biopsy can detect a specific gene mutation (EGFR) in patients with advanced non-small cell lung cancer (NSCLC). The aim is to see if using this test at the time of diagnosis can help doctors make better treatment decisions for patients. This study involves multiple medical centers and is currently looking for participants.

To be eligible for this trial, patients need to be at least 18 years old and have a confirmed diagnosis of non-small cell lung cancer without having started any treatment yet. They must also agree to allow their EGFR status to be tested and provide written consent to participate. During the study, participants can expect to undergo both liquid biopsy and tissue analyses to determine their EGFR gene status. This information could play a significant role in guiding their future treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male or female patients aged ≥ 18 years at time of proposal study,
• • 2. Histologically confirmed non-small cell lung carcinoma,
• • 3. No previous treatment for NSCLC,
• • 4. Indication to EGFR status determination following HAS recommendation,
• • 5. Voluntary signed and dated written informed consent prior to any study specific procedure
• • 6. Patients with a social security in compliance with the French Law.
• Exclusion Criteria:
• • 1. Treatment for advanced NSCLC started before liquid biopsy sampling.
• • 2. Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site).